Global Blood Therapeutics

News
iStock-894635244

GBT heads to FDA with sickle cell drug voxelotor

Global Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of sickle cell disease drug voxelotor as part of a filing for accelerated approval.